COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA

Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combin...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	N. L. Pogudina [verfasserIn] E. G. Kosolapov [verfasserIn] F. S. Kochenkov [verfasserIn] A. V. Karaulov [verfasserIn] N. L. Bondarenko [verfasserIn] D. V. Blinov [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2017

Schlagwörter:	asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis

Übergeordnetes Werk:	In: Фармакоэкономика - IRBIS LLC, 2019, 10(2017), 2, Seite 12-21
Übergeordnetes Werk:	volume:10 ; year:2017 ; number:2 ; pages:12-21

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.17749/2070-4909.2017.10.2.012-021

Katalog-ID:	DOAJ079493866

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ079493866
003	DE-627
005	20230410103223.0
007	cr uuu---uuuuu
008	230307s2017 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.17749/2070-4909.2017.10.2.012-021 \|2 doi
035			\|a (DE-627)DOAJ079493866
035			\|a (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RM1-950
050		0	\|a HB71-74
100	0		\|a N. L. Pogudina \|e verfasserin \|4 aut
245	1	0	\|a COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.
650		4	\|a asthma
650		4	\|a inhaled corticosteroids
650		4	\|a ics
650		4	\|a long-acting beta agonists
650		4	\|a laba
650		4	\|a vilanterol
650		4	\|a fluticasone furoate
650		4	\|a budesonide
650		4	\|a formoterol
650		4	\|a fixed-dose combination
650		4	\|a cost-minimization analysis
650		4	\|a budget impact analysis
653		0	\|a Therapeutics. Pharmacology
653		0	\|a Economics as a science
700	0		\|a E. G. Kosolapov \|e verfasserin \|4 aut
700	0		\|a F. S. Kochenkov \|e verfasserin \|4 aut
700	0		\|a A. V. Karaulov \|e verfasserin \|4 aut
700	0		\|a N. L. Bondarenko \|e verfasserin \|4 aut
700	0		\|a D. V. Blinov \|e verfasserin \|4 aut
773	0	8	\|i In \|t Фармакоэкономика \|d IRBIS LLC, 2019 \|g 10(2017), 2, Seite 12-21 \|w (DE-627)176061677X \|x 20704933 \|7 nnns
773	1	8	\|g volume:10 \|g year:2017 \|g number:2 \|g pages:12-21
856	4	0	\|u https://doi.org/10.17749/2070-4909.2017.10.2.012-021 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 \|z kostenfrei
856	4	0	\|u https://www.pharmacoeconomics.ru/jour/article/view/195 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2070-4909 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2070-4933 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2017 \|e 2 \|h 12-21

Indexfelder

author_variant	n l p nlp e g k egk f s k fsk a v k avk n l b nlb d v b dvb
matchkey_str	article:20704933:2017----::oprtvcsmnmztoadugtmatnlssfiedsihldotcseodogcigeagns
hierarchy_sort_str	2017
callnumber-subject-code	RM
publishDate	2017
allfields	10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21
spelling	10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21
allfields_unstemmed	10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21
allfieldsGer	10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21
allfieldsSound	10.17749/2070-4909.2017.10.2.012-021 doi (DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72 DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 N. L. Pogudina verfasserin aut COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC. asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science E. G. Kosolapov verfasserin aut F. S. Kochenkov verfasserin aut A. V. Karaulov verfasserin aut N. L. Bondarenko verfasserin aut D. V. Blinov verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 10(2017), 2, Seite 12-21 (DE-627)176061677X 20704933 nnns volume:10 year:2017 number:2 pages:12-21 https://doi.org/10.17749/2070-4909.2017.10.2.012-021 kostenfrei https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/195 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2017 2 12-21
language	Russian
source	In Фармакоэкономика 10(2017), 2, Seite 12-21 volume:10 year:2017 number:2 pages:12-21
sourceStr	In Фармакоэкономика 10(2017), 2, Seite 12-21 volume:10 year:2017 number:2 pages:12-21
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis Therapeutics. Pharmacology Economics as a science
isfreeaccess_bool	true
container_title	Фармакоэкономика
authorswithroles_txt_mv	N. L. Pogudina @@aut@@ E. G. Kosolapov @@aut@@ F. S. Kochenkov @@aut@@ A. V. Karaulov @@aut@@ N. L. Bondarenko @@aut@@ D. V. Blinov @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	176061677X
id	DOAJ079493866
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079493866</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2017 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079493866</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. L. Pogudina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled corticosteroids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting beta agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">laba</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vilanterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluticasone furoate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budesonide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">formoterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fixed-dose combination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost-minimization analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budget impact analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. G. Kosolapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">F. S. Kochenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Karaulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. L. Bondarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. V. Blinov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">10(2017), 2, Seite 12-21</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:12-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/195</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">12-21</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	N. L. Pogudina
spellingShingle	N. L. Pogudina misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
authorStr	N. L. Pogudina
ppnlink_with_tag_str_mv	@@773@@(DE-627)176061677X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	20704933
topic_title	RM1-950 HB71-74 COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis
topic	misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science
topic_unstemmed	misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science
topic_browse	misc RM1-950 misc HB71-74 misc asthma misc inhaled corticosteroids misc ics misc long-acting beta agonists misc laba misc vilanterol misc fluticasone furoate misc budesonide misc formoterol misc fixed-dose combination misc cost-minimization analysis misc budget impact analysis misc Therapeutics. Pharmacology misc Economics as a science
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Фармакоэкономика
hierarchy_parent_id	176061677X
hierarchy_top_title	Фармакоэкономика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)176061677X
title	COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
ctrlnum	(DE-627)DOAJ079493866 (DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72
title_full	COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
author_sort	N. L. Pogudina
journal	Фармакоэкономика
journalStr	Фармакоэкономика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
container_start_page	12
author_browse	N. L. Pogudina E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov
container_volume	10
class	RM1-950 HB71-74
format_se	Elektronische Aufsätze
author-letter	N. L. Pogudina
doi_str_mv	10.17749/2070-4909.2017.10.2.012-021
author2-role	verfasserin
title_sort	comparative cost-minimization and budget-impact analysis of fixed-dose inhaled corticosteroid / long-acting betaagonist combinations in the treatment of asthma
callnumber	RM1-950
title_auth	COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
abstract	Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.
abstractGer	Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.
abstract_unstemmed	Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
url	https://doi.org/10.17749/2070-4909.2017.10.2.012-021 https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72 https://www.pharmacoeconomics.ru/jour/article/view/195 https://doaj.org/toc/2070-4909 https://doaj.org/toc/2070-4933
remote_bool	true
author2	E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov
author2Str	E. G. Kosolapov F. S. Kochenkov A. V. Karaulov N. L. Bondarenko D. V. Blinov
ppnlink	176061677X
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.17749/2070-4909.2017.10.2.012-021
callnumber-a	RM1-950
up_date	2024-07-03T23:42:01.001Z
_version_	1803603275679793153
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079493866</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2017 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079493866</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ510e92d40fef4d478021f3c82e9a7a72</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. L. Pogudina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combinations (ICS/LABA) for the treatment of moderate or severe asthma in Russia. Materials andMethods. Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis.Results. The present analysis shows that the 12-month direct medical costs for the treatment of asthma using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient, respectively. The direct costs of treatment with vilanterol / fluticasone furoate are less than those for budesonide / formoterol by 28%. The annual health budget savings that result from replacing budesonide / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients.Conclusion. The present results indicate that the vilanterol / fluticasone furoate FDC is preferable (more beneficial) as compared with the budesonide / formoterol FDC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled corticosteroids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting beta agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">laba</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vilanterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluticasone furoate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budesonide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">formoterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fixed-dose combination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cost-minimization analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">budget impact analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. G. Kosolapov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">F. S. Kochenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Karaulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. L. Bondarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. V. Blinov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">10(2017), 2, Seite 12-21</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:12-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909.2017.10.2.012-021</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/195</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">12-21</subfield></datafield></record></collection>
score	7.4002275

Nicht das Richtige dabei?

Schreiben Sie uns!

COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?